Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.70 |
| ▸ | NPC1 | O15118 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.70 |
| ▸ | CASP3 | P42574 | 1/20 | 0.70 |
| ▸ | RAB9A | P51151 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.70 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.70 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.70 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.70 |
| ▸ | F10 | P00742 | 15/20 | 0.57 |
| ▸ | PRSS12 | P56730 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5534479 | 0.91 | KDM4E (0.73) | MAPTKDM4EMEN1NPC1ALDH1A1 | |
| SCHEMBL16062688 | 0.84 | NPC1 (1.00) | MAPTKDM4EMEN1NPC1ALDH1A1 | |
| SCHEMBL2725087 | 0.79 | MAPT (0.69) | MAPTSMN1; SMN2F10PRSS12 | |
| SCHEMBL2724943 | 0.77 | PRSS12 (0.73) | MAPTPRSS12 | |
| SCHEMBL2723362 | 0.75 | MAPT (0.57) | MAPTF10PRSS12 | |
| SCHEMBL5541503 | 0.75 | MAPT (0.62) | MAPTF10PRSS12 | |
| SCHEMBL31665327 | 0.74 | RAB9A (0.58) | KDM4EMEN1NPC1ALDH1A1RAB9A | |
| SCHEMBL2724682 | 0.74 | PRSS12 (0.82) | MAPTKDM4EMEN1NPC1ALDH1A1 | |
| SCHEMBL5534388 | 0.74 | GCK (0.54) | KDM4EMEN1NPC1ALDH1A1RAB9A | |
| SCHEMBL15295703 | 0.73 | PRSS12 (0.71) | MAPTF10PRSS12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130261130-A1 | NEUROTRYPSIN INHIBITORS | NEUROTUNE AG (CH) | 2013-10-03 | — | — | US | disclosed |
| US-20130261130-A1 | NEUROTRYPSIN INHIBITORS | NEUROTUNE AG (CH) | 2013-10-03 | — | — | US | disclosed |
| WO-2012059442-A2 | NEUROTRYPSIN INHIBITORS | NEUROTUNE AG (CH) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261130-A1 | NEUROTRYPSIN INHIBITORS | MTPN, CHRNA7, CHRNA10 | MAPT 1060/4885KDM4E 3685/4885MEN1 3294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.